About Contact Us Careers
Sign In

Estrogen Receptor Agonist Market Size & Share, by Product Type (Endogenous, Synthetic, Natural); Indication Type (Cancer, Neurodegenerative, Inflammatory, Cardiovascular Diseases); Route of Administration (Oral, Parental); Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Drug Stores, Online Pharmacies) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2023-2035

  • Report ID: 4982
  • Published Date: May 31, 2023
  • Report Format: PDF, PPT

Global Market Size, Forecast, and Trend Highlights Over 2023 - 2035

Estrogen Receptor Agonist Market size is estimated to surpass USD 9 Billion by the end of 2035, witnessing around 7% CAGR during the forecast period, i.e., 2023-2035. In the year 2022, the industry size of estrogen receptor agonist was USD 4 Billion. This rise in market demand is anticipated to be driven by the growing prevalence of cardiovascular disease. According to the World Health Organization, with about 17.9 million deaths per year, cardiovascular diseases (CVDs) are the major cause of death globally. Hence, in order to treat this the demand for different treatments is growing among which estrogen receptor agonist is most preferred. Additionally, it has been proven to be one of the safer treatments for cardiovascular diseases.

Furthermore, women who are in their post-menopausal period are usually given estrogen receptor agonist treatment since they suffer various consequences such as a decline in the concentration of sex steroid hormones in the blood owing to a decline of ovary function. By 2030, the post-menopausal women are projected to reach 1.2 billion, globally.

Estrogen Receptor Agonist Market
Get more information on this report: Request Free Sample PDF

Estrogen Receptor Agonist Sector: Growth Drivers and Challenges

Growth Drivers

  • Growing Prevalence of Osteoporosis 18.3% of people worldwide were estimated to have osteoporosis in 2021. Hence, in order to treat osteoporosis, the demand is on a surge for estrogen receptor agonists. Raloxifene is the most common type of estrogen which is approved by FDA used for this treatment.
  • Rise in Women Suffering from PCOS Between 4% and 20% of women worldwide were believed to have PCOS in 2022. Further, PCOS have a huge adverse effect on female leading to irregular period and acne. Hence, polycystic ovary syndrome treatment on timely basis is necessary. Therefore, in order to control menstrual cycles in PCOS patients, oral contraceptives (OCs; with combined estrogen and progestin) are the most widely used form of medication.
  • Surge in the Application of Estrogen in Asthma There has been growing research on the use of estrogen receptor agonist in the treatment of asthma. Beyond the reproductive system, estrogen plays a variety of tasks in both males and females, including controlling inflammation, intracellular calcium levels, and cell proliferation and differentiation. One of the characteristics of asthma is the infiltration of inflammatory cells such as lymphocytes, monocytes/macrophages, neutrophils, and eosinophils into the airways, particularly eosinophilic infiltration. Hence, it is poised that the estrogen receptor agonist would be used. Hence, further, the investment in research activities on this topic is anticipated to rise in order to prove the conclusion.

Challenges

  • High Cost of Treatment
  • Lack of Processionals who are Skilled in this Field – The use of estrogen receptor agonists is a new form of treatment on which still research is going on for its use to treat different diseases. Hence, not a large number of people are aware of this treatment. Also, since it is not popular enough there is a lack of professionals, especially in rural regions. Hence, this factor is projected to hinder the estrogen receptor agonist market growth.
  • Adverse Effect of Estrogen Receptor Agonist

Estrogen Receptor Agonist Market: Key Insights

Base Year

2022

Forecast Year

2023-2035

CAGR

~ 7%

Base Year Market Size (2022)

 ~ USD 4 Billion

Forecast Year Market Size (2035)

 ~ USD 9 Billion

Regional Scope
  • North America (U.S., and Canada)
  • Latin America (Mexico, Argentina, Rest of Latin America)
  • Asia-Pacific (Japan, China, India, Indonesia, Malaysia, Australia, Rest of Asia-Pacific)
  • Europe (U.K., Germany, France, Italy, Spain, Russia, NORDIC, Rest of Europe)
  • Middle East and Africa (Israel, GCC North Africa, South Africa, Rest of the Middle East and Africa)
Get more information on this report: Request Free Sample PDF

Estrogen Receptor Against Segmentation

Route of Administration (Oral, Parental)

Estrogen receptor agonist market from the oral segment is anticipated to garner the highest revenue by the end of 2035. This segment growth is estimated to boost on account of its cost efficiency. Since parenteral drugs must be sterile and isotonic, the oral pharmaceuticals on the market are less expensive, which results in financial savings for the patient. Moreover, oral medication gets absorbed at a faster rate. Hence, they are most preferred.

Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Drug Stores, Online Pharmacies)

The hospital pharmacies segment in the estrogen receptor agonist market is set to have noteworthy growth over the forecast period. Most of estrogen receptor agonist drugs are prescribed by the doctors. Hence, the pharmacies attached to the hospitals are estimated to satisfy the growing demand for this medication.

Our in-depth analysis of the global market includes the following segments:

 

    Product Type
  • Endogenous
  • Synthetic
  • Natural

    Indication Type
  • Cancer
  • Neurodegenerative Diseases
  • Inflammatory Diseases
  • Cardiovascular Diseases

 

    Route of Administration
  • Oral
  • Parental

 

 

    Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Drug Stores
  • Online Pharmacies

Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.

Customize this Report

Estrogen Receptor Agonist Industry - Regional Synopsis

APAC Market Statistics

The Asia Pacific estrogen receptor agonist market is set to have the highest growth by the end of 2035, backed by the growing geriatric population in this region. In Asia and the Pacific region, one in four persons is expected to be older than 60 by 2050. Moreover, this transition is expected to happen relatively quickly in several nations, such as the People's Republic of China, Sri Lanka, Thailand, and Viet Nam. Hence, the demand for estrogen receptor agonist is poised to grow. Old people are prone to various diseases such as cardiovascular disease, asthma, and more. Hence, in order to treat or prevent the growth of disease, the market is estimated to grow.

North American Market Forecast

The North America estrogen receptor agonist market is projected to have significant growth over the forecast period. The market in this region is poised to grow on account of rising cases of cancer.

Research Nester
Estrogen Receptor Agonist Market Size
Get more information on this report: Request Free Sample PDF

Companies Dominating the Estrogen Receptor Agonist Landscape

top-features-companies
    • AstraZeneca
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • Eli Lilly and Company
    • ESTRIGENIX
    • Karo Healthcare AB
    • Merck KGaA
    • Vivesto AB
    • Oncternal Therapeutics
    • Pfizer Inc.
    • Tocris Bioscience
    • Tokyo Chemical Industry Co., Ltd

In the News

  • Positive high-level findings from the FLAURA2 Phase III trial showed that Tagrisso (osimertinib) from AstraZeneca improved progression-free survival (PFS) among individuals with locally advanced (Stage IIIB-IIIC) or metastatic (Stage IV) epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC) more significantly when combined with chemotherapy than when used alone.
  • On Thursday, October 27, and Friday, October 28, at the Grand Hyatt at San Francisco Airport, located at 55 South McDonnell Road in San Francisco, Estrigenix Therapeutics, Inc. presented new research on hormone replacement treatment.

Author Credits:  Radhika Gupta, Shivam Bhutani


  • Report ID: 4982
  • Published Date: May 31, 2023
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

The major factors driving the growth of the market are the growing prevalence of osteoporosis, the rise in women suffering from PCOS, and the surge in the application of estrogen in asthma.

The market size of estrogen receptor agonist is anticipated to attain a CAGR of 7% over the forecast period, i.e., 2023-2035.

The major players in the market are AstraZeneca, Eli Lilly and Company, ESTRIGENIX, Karo Healthcare AB, and more.

The company profiles are selected based on the revenues generated from the product segment, the geographical presence of the company which determines the revenue generating capacity as well as the new products being launched into the market by the company.

The market is segmented by product type, indication type, route of administration, distribution channel and by region.

The oral segment is anticipated to garner the largest market size by the end of 2035 and display significant growth opportunities.

High cost of treatment, lack of professions who are skilled in this field, and adverse effect of estrogen receptor agonist are estimated to be the growth hindering factors for the market expansion.

The market in the Asia Pacific region is projected to hold the largest market share by the end of 2035 and provide more business opportunities in the future.
Estrogen Receptor Agonist Market Report Scope

Copyright © 2024 Research Nester. All Rights Reserved

logo
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying